When DRI Healthcare Trust acquired a synthetic royalty stake in the U.S. sales of the thyroid eye disease (TED) therapies veligrotug and VRDN-003, attorneys from Ballard Spahr’s national Intellectual Property Department provided legal and regulatory advice.